IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Curis Lifesciences
IPO is a SME Upcoming IPO coming on
NSE EMERGE with an
IPO
size of
[●]
.
This IPO falls under the
Pharmaceutical sector, which has seen
40 IPOs
to date. Key sector metrics such as average PE ratio, IPO size, EBITDA margin,
and
PAT margin are compared below with the figures from the
Curis Lifesciences
IPO.
Curis Lifesciences IPO Peer Comparison with key metrics mentioned in the DRHP.
| Company Name | CMP | Face Value | Adjusted Basic EPS | Adjusted Diluted EPS | P/E | RoNW | NAV per Share | Total Income (Cr.) |
|---|---|---|---|---|---|---|---|---|
| Curis Lifesciences Limited | 10 | 8.52 | 8.52 | 84.12 | 10.13 | 35.89 | ||
| Lincoln Pharmaceuticals Ltd | 551.5 | 10 | 41.11 | 41.11 | 13.42 | 12.27 | 335.34 | 645.71 |
| Sotac Pharmaceuticals Limited | 118.75 | 10 | 4.32 | 4.32 | 27.49 | 9 | 47.99 | 64.76 |
(i) The EPS, NAV, RoNW and total Income of our Company are taken as per Restated Financial Statement for the
Financial Year 2023-24.
(ii) NAV per share of our company is computed as the closing net worth divided by the weighted average number of
paid up equity shares as on March 31, 2024. NAV per share of peers company is computed as the closing net worth
divided by the weighted average number of paid up equity shares as on March 31, 2025.
(iii) RoNW has been computed as net profit after tax divided by closing net worth.
(iv) Net worth has been computed in the manner as specifies in Regulation 2(1)(hh) of SEBI (ICDR) Regulations, 2018.
The face value of Equity Shares of our Company is ₹ 10/- per Equity Share and the Issue price is [●] times of the face
value of equity share
Source – All the financial information for listed industry peers mentioned above is sourced from the published results
of the aforesaid companies for the year ended March 31, 2025 and stock exchange data dated 31/03/2025 to compute
the corresponding financial ratios. For our Company, current market price and PE ratio of our company will be
determined at the end of book building process. For peer companies, P/E Ratio is based on the market price as on
March 28, 2025 and March 28, 2025 for Sotac Pharmaceuticals Limited and Lincoln Pharmaceuticals Limited,
respectively.
You can do performance analysis for Curis Lifesciences IPO with Listed IPOs in the Pharmaceutical sector and review their IPO performance based on Merchant banker, Listing price, IPO Valuation and other metrics.
This IPO report captures the post-listing performance of IPOs in the Pharmaceutical sector, featuring key metrics like offer price, listing gain, and CMP to help investors assess return potential and sector sentiment.
Curis Lifesciences IPO Draft red herring prospectus (DRHP) and Red Herring prospectus (RHP) are available below.
The peers of
Curis Lifesciences ,
include other listed companies operating in the
(Pharmaceutical) segment. These peer companies
typically
offer similar services Some of the notable peers as per the DRHP of this
company
are
Curis Lifesciences Limited ,
Lincoln Pharmaceuticals Ltd
Sotac Pharmaceuticals Limited ,
.
See the complete list of
current IPO
Peer Comparison is the method of evaluating an entity by comparing its performance, size of business form other entities operating in same industry or sector. It involves financial analysis bycomparing key financial metrics like Profitability, Net worth, Market Capitalization and Leverage. Peer comparison is beneficial for investors to make informed investment decisions and to identify any potential risks. IPO Performance tracker
Peer comparison helps to identify companies in the same sector with a similar business. It helps to compare the financial performance and valuation against its listed peers. An investor or an analyst can decide whether the IPO price is justified when compared to its peers. An investor can make informed decision whether to apply to IPO or not on basis of peer comparison. Know the process of DRHP and Peer companies Information required to be disclosed in DRHP.
As of now 40 SME IPOs are listed in this sector indicating strong growth in this sector. Choosing the best IPO depends on factors like, financial performance, valuation, market trends and future growth plans. IPO Review and performance.
A good PE Ratio for Pharmaceutical sector depends on various factors like, performance of the company, market conditions, company valuation and IPO Size. PE Ratio varies from sector to sector and company to company. Know the average PE Multiple in each sector.
Currently 40 companies are listed under Pharmaceutical sector. Based on the latest data from the Stock Exchanges. Choose the Best Merchant Banker from the Merchant Banker List
Performance of companies depends on various factors like, profits, future plans, Market share, PE Ratio etc. By assessing these factors investor can make better investment decisions.Curis Lifesciences Peer comparison provides IPO analysis of companies listed in this sector, on the basis of different Key performance indicators (KPI)like, Listing Gain of peers, current market price, PE Ratio and IPO Size.
Upcoming IPO refers to companies which have filed their DRHP with the Stock exchange and are awaiting approval from NSE Emerge or BSE SME. 12 companies have filed their DRHP for SME IPO under Pharmaceutical sector. .New IPO 2025-2026 and Upcoming IPO
PE Multiple is a metrics that is widely used for IPO Valuation. Merchant bankers in coordination with the company decides the PE Multiple.The PE Multiple depends on various factors and it should be analyzed in coordination with other financial metrics. Know the PE ratio of your company with PE Calculator provided by IPOplatform
Curis Lifesciences operates in Pharmaceutical and . The Issue is listed on NSE EMERGE in Aug, 2025. Curis Lifesciences IPO size was with Issue price of .
Merchant Banker(s) of Curis Lifesciences IPO: Swastika Investmart Limited
Curis Lifesciences IPO subscription was X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Curis Lifesciences IPO listed at a listing price of against the offer price of .
The current market price of Curis Lifesciences is .
Why Us?
